Development of an oral treatment with the PPAR-γ-acting cannabinoid VCE-003.2 against the inflammation-driven neuronal deterioration in experimental Parkinson’s disease

EDUARDO MUÑOZ BLANCO2026-01-292026-01-29201910.3390/molecules241527022-s2.0-85070110316https://www.scopus.com/inward/record.uri?eid=2-s2.https://ucocris.uco.es/handle/123456789/30681Analytical ChemistryChemistry (miscellaneous)Drug DiscoveryMolecular MedicineOrganic ChemistryPharmaceutical SciencePhysical and Theoretical ChemistryDevelopment of an oral treatment with the PPAR-γ-acting cannabinoid VCE-003.2 against the inflammation-driven neuronal deterioration in experimental Parkinson’s diseaseresearch article